| Primary Identifier | IPR015611 | Type | Family |
| Short Name | TIMP1 |
| description | TIMP-1 (also known as metalloproteinase inhibitor 1) was originally knocked-out and found to be indistinguishable from wild-type mice in metastasis assays with all tumourgenic cells tested []. Since then, studies have demonstrated that myocardial TIMP-1 plays a regulatory role in post-myocardial infarction remodeling and that myocardial remodeling is accelerated induced TIMP-1 gene deletion []. Transfer and over expression of the Timp1 gene may be a promising therapeutic strategy to target tumour-associated angiogenesis in cancer gene therapy []. Also, TIMP-1-deficient mice are resistant to Pseudomonas aeruginosa corneal and respiratory infections []. Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of matrix metalloproteinases (MMPs) found in most tissues and body fluids. By inhibiting MMPs activities, they participate in tissue remodeling of the extracellular matrix (ECM). The balance between MMPs and TIMPs activities is involved in both normal and pathological events such as wound healing, tissue remodeling, angiogenesis, invasion, tumourigenesis and metastasis []. TIMPs also exhibit functions that appear to be independent of their metalloproteinase inhibitory capacity []. There are four mammalian TIMPs (TIMP-1 to -4), and each TIMP has its own profile of metalloproteinase inhibition. |
